The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Contrast-enhanced T1-weighted subtraction maps for response assessment in recurrent glioblastoma treated with bevacizumab.
Benjamin M. Ellingson
Consultant or Advisory Role - Genentech (U); MedQIA
Hyun J. Kim
Consultant or Advisory Role - Genentech (U); MedQIA
Davis C. Woodworth
No relevant relationships to disclose
Whitney B. Pope
Consultant or Advisory Role - Genentech; MedQIA
Jonathan N. Cloughesy
No relevant relationships to disclose
Robert J. Harris
No relevant relationships to disclose
Albert Lai
Consultant or Advisory Role - Genentech
Research Funding - Genentech
Phioanh L. Nghiemphu
Consultant or Advisory Role - Genentech (U)
Timothy F. Cloughesy
Consultant or Advisory Role - Genentech; Roche